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Chimpanzees in west central Africa (Pan troglodytes troglodytes) are endemically infected with simian immunodeﬁciency vi-
ruses (SIVcpzPtt) that have crossed the species barrier to humans and gorillas on at least ﬁve occasions, generating pandemic
and nonpandemic forms of human immunodeﬁciency virus type 1 (HIV-1) as well as gorilla SIV (SIVgor). Chimpanzees in east
Africa (Pan troglodytes schweinfurthii) are also infected with SIVcpz; however, their viruses (SIVcpzPts) have never been found
in humans. To examine whether this is due to a paucity of natural infections, we used noninvasive methods to screen wild-living
eastern chimpanzees in the Democratic Republic of the Congo (DRC), Uganda, and Rwanda. We also screened bonobos (Pan
paniscus) in the DRC, a species not previously tested for SIV in the wild. Fecal samples (n 3,108) were collected at 50 ﬁeld sites,
tested for species and subspecies origin, and screened for SIVcpz antibodies and nucleic acids. Of 2,565 samples from eastern
chimpanzees, 323 were antibody positive and 92 contained viral RNA. The antibody-positive samples represented 76 individuals
from 19 ﬁeld sites, all sampled north of the Congo River in an area spanning 250,000 km
2. In this region, SIVcpzPtswas common
and widespread, with seven ﬁeld sites exhibiting infection rates of 30% or greater. The overall prevalence of SIVcpzPtsinfection
was 13.4% (95% conﬁdence interval, 10.7% to 16.5%). In contrast, none of the 543 bonobo samples from six sites was antibody
positive. All newly identiﬁed SIVcpzPtsstrains clustered in strict accordance to their subspecies origin; however, they exhibited
considerable genetic diversity, especially in protein domains known to be under strong host selection pressure. Thus, the ab-
sence of SIVcpzPtszoonoses cannot be explained by an insufﬁcient primate reservoir. Instead, greater adaptive hurdles may have
prevented the successful colonization of humans by P. t. schweinfurthii viruses.
O
fover40Africanprimatespeciesnaturallyinfectedwithsim-
ian immunodeﬁciency viruses (SIVs), chimpanzees (Pan
troglodytes)areuniquebecausetheyharborthevirus(SIVcpz)that
spawned the human AIDS pandemic (20, 30, 78). It is now well
established that chimpanzees are the original source of viruses
currently found in chimpanzees, gorillas, and humans and that
ape viruses have been transmitted to humans on at least four oc-
casions, generating human immunodeﬁciency virus type 1
(HIV-1) groups M, N, O, and P (24, 64, 65). Chimpanzees also
differ from most other primate species by having acquired their
infection relatively more recently, as a consequence of cross-spe-
ciestransmissionandrecombinationofvirusesinfectingmonkeys
on which they prey (3). Importantly, natural history studies have
shown that SIVcpz is quite pathogenic and has a substantial neg-
ative impact on the health, reproduction, and life span of its nat-
ural host (17, 29, 54, 74). Thus, in addition to representing a po-
tential source for human infection, SIVcpz also comprises a
serious threat to chimpanzee populations living in the wild (54).
Chimpanzees are highly endangered, thus requiring noninva-
siveapproachestostudySIVcpzinfectioninwildpopulations(59,
60). To address this, we have—over the past decade—developed
approaches that permit the detection of virus-speciﬁc antibodies
andnucleicacidsinfecalandurinesamples(29,30,35a,41,54,55,
58, 59, 72, 73, 78, 79, 84). Examining the molecular epidemiology
ofSIVcpzinthewild,wefoundthatonlytwoofthefourcurrently
recognizedsubspecies(9),i.e.,central(Pantroglodytestroglodytes)
and eastern (Pan troglodytes schweinfurthii) chimpanzees but not
western (Pan troglodytes verus) and Nigeria-Cameroonian (Pan
troglodytes ellioti) chimpanzees, are naturally infected by SIVcpz
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 (30, 35, 55, 58, 59, 78). We also found that SIVcpz is unevenly
distributed among wild apes, with high prevalence rates (up to
50%) in some communities and rare or absent infection in others
(29,30,54,55,59,78).MolecularstudiesofexistingSIVcpzstrains
revealed that they cluster in accordance to their subspecies origin
intwohighlydivergentlineages,termedSIVcpzPttandSIVcpzPts
(65). Interestingly, all groups of HIV-1 as well as viruses (SIVgor)
from western gorillas (Gorilla gorilla gorilla) fall into just one of
these lineages, clustering with SIVcpzPtt from P. t. troglodytes,
which implicates the central subspecies as the source of both hu-
man and gorilla infections (30, 65, 72, 79). In contrast, evidence
for transmission of SIVcpzPts strains to either humans or sympa-
triceasterngorillas(Gorillagorillaberingei)islacking(41),raising
questions as to the relative abundance and distribution of SIVcpz
in wild-living P. t. schweinfurthii populations (45).
EasternchimpanzeesliveincentralandeastAfrica(Fig.1A)in
an area that ranges from the southeastern parts of the Central
African Republic (CAR) through the northern parts of the Dem-
ocratic Republic of Congo (DRC) to southwestern Sudan and the
western parts of Uganda, Rwanda, Burundi, and Tanzania (50).
TheﬁrstSIVcpzPtsstrain(ANT)wasidentiﬁedinanapecaptured
atanunknownlocationintheDRCandexportedtoBelgium(20,
44,76).Subsequenttestingoffecalsamplesfromalimitednumber
of chimpanzees in the vicinity of Kisangani indicated that
SIVcpzPts was also present in wild-living P. t. schweinfurthii com-
munitiesintheDRC(84).However,extensiveﬁeldstudiesineast
Africa revealed a surprising paucity of SIVcpzPts infections. Al-
though infected chimpanzees were identiﬁed in Gombe National
Park (GM) (29, 54, 59, 60) and the Ugalla region (UG) of western
Tanzania (55), communities in the Budongo Forest (BG) in
northern Uganda, the Kibale National Park (KB) in western
Uganda, the Bwindi Impenetrable Forest (BW) in southern
Uganda,andMahaleMountainsNationalPark(MH)inTanzania
seemed free of SIVcpz infection (55, 59, 66). Moreover, none of
over 300 fecal samples from the Nyungwe Forest Reserve (NY) in
western Rwanda was virus positive (66). Thus, in contrast to the
high infection rates observed for P. t. troglodytes apes in southern
Cameroon (30, 41, 78) and northern Gabon (35a) ﬁeld studies at
the eastern limits of the P. t. schweinfurthii range identiﬁed only
isolated foci of infection.
The habitat of eastern chimpanzees in Uganda, Rwanda, and
Tanzania is severely fragmented (Fig. 1B) due to extensive defor-
estation, expanding agriculture, and human encroachment (50).
To test whether this habitat loss might have contributed to the
paucity of SIVcpzPts infections in east Africa, we targeted wild-
living apes in the Democratic Republic of the Congo, a country
that is home to half of the world’s remaining chimpanzees (10,
50). There are two different chimpanzee species in the DRC, the
eastern chimpanzee (Pan troglodytes schweinfurthii) and the bo-
nobo (Pan paniscus), who live in nonoverlapping ranges north
andsouthoftheCongoRiver,respectively(Fig.1A).Currentpop-
ulation estimates suggest that there may be as many as 180,000 to
200,000 eastern chimpanzees and 30,000 to 50,000 bonobos still
remaining in largely intact forest blocks (10, 19, 50). With the
exception of one study (84), wild-living apes in the DRC have not
previously been surveyed for SIV. Here, we show that eastern
chimpanzees, but not bonobos, are widely and commonly in-
fectedwithSIVcpzPtsandthusrepresentasubstantialvirusreser-
voir.
MATERIALS AND METHODS
Studysitesandsamplecollection.Thevastmajorityofapefecalsamples
werecollectedintheDRCfromnonhabituatedeasternchimpanzees(n 
2,480) and bonobos (n   543) by teams of local trackers (Table 1). Sam-
ples were collected in the vicinity of chimpanzee night nests or when
encountered during forest walks, placed into 50-ml conical tubes, and
preserved in an equal volume of RNAlater (Life Technologies) as de-
scribedpreviously(30,59,78).Tubeswerelabeledwithasamplenumber,
the ﬁeld site code, and GPS coordinates when available. Because local
trackers were participating in the collection effort, the quality of samples
varied between ﬁeld sites and individual specimens were frequently di-
vided into multiple aliquots without this being indicated. In four in-
stances,sampleswerecollectedfrompetchimpanzeeskeptbylocalvillag-
ers(BU203,KS133,KS134,andKS135).Sampleswerealsocollectedfrom
habituated chimpanzee communities in the Budongo Reserve (BG) in
northernUganda(n 20)(52)andtheKyamburaGorge(KY)inwestern
Uganda (n   16) (32). At the latter two sites, fecal samples were collected
from individually known apes under direct observation by resident pri-
matologists. Finally, samples were obtained from nonhabituated chim-
panzeesintheGishwatiForest(GI)innorthwesternRwanda(n 49)(12,
49). Because of a lack of refrigeration at most ﬁeld sites, especially in the
DRC, samples were kept at ambient temperature for various periods of
time(usuallyseveralweeks,butinsomeinstancesseveralmonths)before
they could be stored at  20°C. In the DRC, this was done at a central
laboratoryinKisangani,wheresampleswerethenbatchedandshippedto
the United States. Bonobo samples from the Malebo (ML) ﬁeld site were
stored at  80°C at the Institut National de Recherche Biomédicale in
Kinshasa and then shipped directly to the University of Montpellier.
SIVcpz antibody detection. All fecal samples were screened for the
presence of HIV-1 cross-reactive antibodies as previously described (30,
41, 59, 78). Bonobo samples from the ML ﬁeld site were tested using the
Inno-LIA HIV I/II Score test (Innogenetics, Ghent, Belgium) (78). All
other samples were examined by an enhanced chemiluminescence (ECL)
Western immunoblot analysis modiﬁed for RNAlater-preserved speci-
mens. RNAlater is a high-salt solution (25 mM sodium citrate, 10 mM
EDTA, and 70 g ammonium sulfate per 100 ml of solution; pH 5.2) that
preserves nucleic acids but precipitates proteins, including immunoglob-
ulin. To prepare extracts suitable for a Western blot analysis, feces-
RNAlater mixtures (1.5 ml) were diluted with phosphate-buffered saline
(PBS)-Tween 20 (8.5 ml), inactivated for 1 h at 60°C, clariﬁed by centrif-
ugation (3,500   g for 30 min) to remove solid debris, and then dialyzed
against PBS overnight at 4°C to reconstitute fecal immunoglobulin. Re-
constitutedextractsweresubjectedtoanimmunoblotanalysisusingcom-
mercially available HIV-1 antigen-containing strips (Maxim Biomedical,
Inc.). Sample integrity was examined using an IgG control.
Ampliﬁcation of SIVcpz virion RNA. All Western blot-positive sam-
plesweretestedforthepresenceofSIVnucleicacidsbyreversetranscrip-
tion-PCR(RT-PCR)ampliﬁcationasdescribedpreviously(30,37,41,59,
78).Brieﬂy,fecalRNAwasextractedusingtheRNAqueous-MidiKit(Life
Technologies)andsubjectedtoRT-PCRampliﬁcationusingSIVcpz-spe-
ciﬁc gag, pol, vpu, gp41, and gp41/nef consensus primers (see Table S1 in
the supplemental material). PCR conditions generally included 60 cycles
ofdenaturation(94°C,20s),annealing(50°C,30s),andelongation(68°C,
1.5 min) for the ﬁrst round. Second-round conditions included 50 cycles
ofdenaturation(94°C,20s),annealing(52°C,30s),andelongation(68°C,
1 min). All amplicons were gel puriﬁed and sequenced directly. Samples
that failed to yield SIVcpz amplicons were reampliﬁed using pan-SIV-
speciﬁc primers (see Table S1 in the supplemental material) so as to not
miss infection with SIVs other than SIVcpz.
Individual identiﬁcation. All fecal samples were subjected to mito-
chondrial (mt) DNA analysis to conﬁrm their species and subspecies or-
igin. In addition, all antibody-positive P. t. schweinfurthii samples as well
as 146 bonobo samples from three different ﬁeld sites (IK, LK, and KR)
were subjected to microsatellite analyses. Fecal DNA was extracted as
described and used to amplify a 498-bp fragment of the mitochondrial
Widespread SIVcpz Infection in Eastern Chimpanzees
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 FIG 1 Location of ape study sites. (A) Geographic ranges of chimpanzees (Pan troglodytes) and bonobos (Pan paniscus) in Saharan Africa. The four recognized
chimpanzeesubspeciesarecolorcoded(P.t.verus,gray;P.t.ellioti,purple;P.t.troglodytes,blue;P.t.schweinfurthii,yellow).Internationalborders,majorrivers
and lakes, and select cities are shown. Asterisks indicate where the closest SIVcpz relatives of HIV-1 groups M (red) and N (green) were identiﬁed in wild-living
P.t.troglodytescommunities(30).Aboxoutlinesthestudyarea,whichismagniﬁedinpanelB.(B)Locationofchimpanzee(circles)andbonobo(squares)study
sites in the DRC, Uganda, and Rwanda. The ranges of eastern chimpanzees (yellow) and bonobos (orange) are shown as in panel A. Sites where SIVcpz was
detected are indicated in red, with white and yellow lettering denoting the recovery of antibody-positive and antibody- and nucleic acid-positive samples,
respectively. Previously published SIVcpz-positive and -negative sites in Uganda, Rwanda, and Tanzania are shown in dark red and gray, respectively. Forested
areasareshowningreen,whilearidandsemiaridareasareinyellowandbrown.Majorlakesareshowninblack,withmajorriversdepictedinblue.Dashedwhite
lines indicate national boundaries.
Li et al.
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 D-loopregion(30,38,59).Ampliconsweresequenceddirectly(usingone
primer which yielded 479 bp of sequence) and classiﬁed into distinct
mitochondrial haplotypes (see Fig. S1 and Table S2 in the supplemental
material). To identify the number of sampled individuals, fecal samples
were genotyped at four (P. t. schweinfurthii) or eight (P. paniscus) auto-
somal microsatellite loci (see Tables S3 and S4 in the supplemental mate-
rial), with ampliﬁcation products sized on an automated sequencer using
GeneMapper 4.0 (Applied Biosystems). Samples were ﬁrst grouped by
ﬁeld site and mtDNA haplotype. Within each haplotype, samples were
thengroupedbymicrosatellitegenotypesand,whenpossible,alsobygen-
der and viral genotype. Due to prolonged storage at ambient tempera-
tures, even mtDNA-positive samples were frequently partially degraded.
Wethusallowedallelicmismatchesatuptofour(easternchimpanzees)or
six(bonobos)lociifothermarkers(mtDNAhaplotype,gender)indicated
possible identity. This very conservative approach likely resulted in an
underestimation of the number of sampled individuals. Samples with
TABLE 1 Prevalence of SIVcpz infection in wild-living eastern chimpanzees and bonobos
a
Species and
subspecies Field site
b
No. of
fecal
samples
collected
No. of fecal
samples
positive for
mtDNA
Proportion of
degraded/
mixed
samples
No. of
individuals
sampled
c
No. of
mtDNA
haplotypes
d
No. of
SIVcpz
antibody-
positive
samples
No. of
infected
individuals
e
No. of vRNA-
positive
samples
SIVcpz
prevalence
(%)
f
95%
conﬁdence
interval of
SIVcpz
prevalence
P. t. schweinfurthii Amunyala (AM) 44 37 0.16 NA 5 15 3 3 33 2–43
Ango (AN) 16 15 0.06 NA 1 0 0 0 0 0–60
Azunu (AZ) 6 5 0.17 3 2 4 2 0 67 9–99
Bafwaboli (BA) 256 229 0.11 NA 22 39 5 1 9 3–20
Bondo (BD) 15 15 0.00 NA 9 0 0 0 0 0–34
Baego (BE) 134 87 0.35 NA 18 0 0 0 0 0–17
Bafwasende (BF) 42 37 0.12 NA 7 12 1 12 11 0–48
Babingi (BI) 124 103 0.17 NA 14 0 0 0 0 0–14
Bongbola (BL) 50 48 0.04 NA 21 3 2 2 10 1–30
Bomili (BM) 47 43 0.09 NA 2 0 0 0 0 0–31
Biruwe (BR) 59 59 0.00 NA 1 0 0 0 0 0–23
Basoco (BS) 20 10 0.50 NA 8 0 0 0 0 0–37
Buta (BT) 5 4 0.20 NA 4 0 0 0 0 0–60
Bumba (BU) 1 1 0.00 NA 1 1 1 0 100 3–100
Dingila (DL) 5 5 0.00 NA 1 0 0 0 0 0–98
Epulu (EP) 160 126 0.21 NA 19 7 2 4 7 1–22
Gombari (GO) 5 2 0.60 NA 2 0 0 0 0 0–84
Ijela (IJ) 27 7 0.74 NA 2 0 0 0 0 0–84
Isiro (IS) 5 4 0.20 NA 3 0 0 0 0 0–71
Kabuka (KA) 164 126 0.23 NA 23 33 13 10 43 25–63
Kasese (KE) 15 7 0.53 NA 3 0 0 0 0 0–71
Kotakoli (KO) 90 78 0.13 NA 12 9 1 0 6 0–27
Kisangani (KS) 13 11 0.15 NA 8 4 3 0 38 9–76
Lubutu (LU) 212 163 0.23 NA 18 34 3 27 8 2–21
Mawa Gare (MA) 11 7 0.36 NA 1 0 0 0 0 0–84
Mount Mogogoli (MN) 2 1 0.50 NA 1 0 0 0 0 0–98
Mongandjo (MO) 21 15 0.29 NA 10 2 1 2 10 0–45
Mungbere (MU) 58 53 0.09 NA 11 26 6 3 50 21–79
Niangara (NI) 7 4 0.43 NA 2 0 0 0 0 0–84
Onga (ON) 59 40 0.32 NA 4 0 0 0 0 0–34
Opienge (OP) 85 61 0.28 NA 9 26 2 18 14 2–43
Parisi (PA) 131 110 0.16 NA 16 48 12 5 46 27–67
Poko (PO) 11 10 0.09 NA 6 0 0 0 0 0–46
Rungu (RU) 18 13 0.28 NA 4 0 0 0 0 0–60
Ubangi (UB) 117 99 0.15 NA 23 11 7 3 30 13–53
Ubundu (UD) 5 5 0.00 NA 2 0 0 0 0 0–84
Uma (UM) 100 61 0.39 NA 10 0 0 0 0 0–23
Wanie Rukula (WA) 170 151 0.11 NA 25 40 8 1 22 10–39
Wamba (WB) 91 69 0.24 NA 11 8 3 1 19 4–46
Walikale (WK) 35 33 0.06 NA 10 0 0 0 0 0–31
Walengola (WL) 44 39 0.11 NA 13 1 1 0 8 0–36
Budongo (BG) 20 19 0.05 19 9 0 0 0 0 NA
Kyambura Gorge (KY) 16 16 0.00 13 4 0 0 0 0 NA
Gishwati (GI) 49 42 0.14 NA 6 0 0 0 0 0–31
All sites (n   44) 2,565 2,070 0.19 567
i 383 323 76 92 13.4 10.7–16.5
P. paniscus Bayandjo (BJ) 22 0 NA 1 00 0 0 0–98
Balanga (BN) 96 85 0.12 NA 7 00 0 0 0–8
Ikela (IK) 56 39 0.30 17 7 00 0 0 0–20
kokolopori (KR) 78 69 0.12 38 12 0 0 0 0 0–9
Lui Kotale (LK) 43 38 0.12 17 8 00 0 0 0–20
Malebo (ML) 268 262 0.02 NA 6 00 0 0 0–3
All sites (n   6) 543 495 0.09 244
i 41 0 0 0 0 0–1.5
a vRNA, virion RNA; NA, not available.
b Field site locations are shown in Fig. 1.
c Chimpanzees at the BG and KY ﬁeld sites were individually known. For the AZ, IK, KR, and LK ﬁeld sites, the number of sampled apes was determined by microsatellite analyses
(see Tables S3 and S4 in the supplemental material).
d Minimum number of individuals, as indicated by the number of distinct mtDNA haplotypes.
e SIVcpz-infected chimpanzees were enumerated for each ﬁeld site by microsatellite analysis of antibody-positive fecal samples (see Table S3 in the supplemental material).
f Prevalence of SIVcpz infection (%) with 95% conﬁdence intervals. Values are based on the proportions of SIVcpz antibody-positive fecal samples, corrected for sample
degradation and oversampling.
g The single sample from the BU ﬁeld site was collected from a pet chimpanzee.
h Samples from the KS ﬁeld site include three from pet chimpanzees.
i Estimated number of sampled individuals (see Materials and Methods for details).
Widespread SIVcpz Infection in Eastern Chimpanzees
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 evidenceofDNAadmixture(multiplepeaksforthesamelocusordouble
peaks in the mtDNA sequence) were excluded.
Gender determination. For most samples, gender was determined by
amplifyinga218-bpfragmentoftheamelogeningenethatcontainsa6-bp
insertionintheY,butnottheX,chromosomeusingprimersAMEL-F212
(5=-ACCTCATCCTGGGCACCCTGG-3=) and AMEL-R212 (5=-AGGCT
TGAGGCCAACCATCAG-3=)( 69). PCR conditions were the same as
those for the microsatellite analyses, and fragments were sized on an au-
tomatedsequencer.Forsamplesthatfailedthisgenotyping,asecondsetof
amelogenin primers (AMXY-1F [5=-CTGATGGTTGGCCTCAAGCCTG
TG-3=] and AMXY-2R [5=-TAAAGAGATTCATTAACTTGACTG-3=])
were used to amplify a 977-bp fragment from the X chromosome and a
788-bp fragment from the Y chromosome. The resulting PCR products
were sized by 1.2% agarose gel electrophoresis (16, 59).
SIVcpz prevalence determination. The prevalence of SIVcpz infec-
tion was estimated for each ﬁeld site based on the proportion of SIVcpz
antibody-positive fecal samples, correcting for degradation and redun-
dant sampling. As shown in Table 1, 19% of eastern chimpanzee and 9%
ofbonobofecalsamplesfailedtoyieldusablemtDNAsequencesandwere
thus excluded from further analysis. A subset of the remainder was then
subjected to microsatellite analyses, which provided a quantitative esti-
mateofoversamplingforbothspecies.ForP.t.schweinfurthii,genotyping
of 323 antibody-positive fecal samples from 19 ﬁeld sites identiﬁed 76
infected individuals (Table 1), indicating that each had been sampled, on
average, 4.25 times (see Table S3 in the supplemental material). For bo-
nobos, analysis of 146 fecal samples from three ﬁeld sites identiﬁed 72
individuals (Table 1), indicating that each had been sampled, on average,
2.03 times (see Table S4 in the supplemental material). Using these cor-
rections, the proportion of SIVcpz-infected chimpanzees was estimated
for each sampling location, taking into account the number of unique
mtDNAhaplotypesasanindicatoroftheminimumnumberofchimpan-
zees tested. From these determinations, prevalence rates were calculated
(95% conﬁdence limits were calculated based on binomial sampling).
Full-length genome ampliﬁcation. The full-length genome of one
representativeSIVcpzPtsstrainfromtheDRC(BF1167)wassequencedas
described previously (58, 78). Brieﬂy, partially overlapping subgenomic
fragments were ampliﬁed from fecal RNA, gel puriﬁed, and sequenced
directly. Chromatograms were examined for positions of base mixtures,
and ambiguous sites were resolved as previously reported (7, 55, 72, 73).
For positions that did not affect the corresponding amino acid, the pre-
dominant nucleotide (highest amplitude in the sequence chromatogram
or the most frequent nucleotide in repeat sequencing reactions) was cho-
sen. For positions that affected the corresponding amino acid, the base
that encoded the most common amino acid residue in alignments of
existing SIVcpz protein sequences was selected. In the absence of an ap-
parent common amino acid (e.g., in hypervariable protein regions), the
nucleotide with the highest amplitude in sequence chromatograms was
selected. Using these criteria, we were able to infer a unique consensus
sequence for BF1167.
Construction of a replication-competent SIVcpzPts molecular
clone. To obtain a full-length infectious molecular clone of BF1167, the
consensussequencewaschemicallysynthesizedasthreesubgenomicfrag-
ments (Blue Heron Biotechnology). These included a 3.7-kb 5= long ter-
minalrepeat(LTR)-polfragment,a3.9-kbpol-envfragment,anda2.3-kb
env-3= LTR fragment. To facilitate subsequent cloning, unique MluI and
ApaIsiteswereaddedtothe5=and3=terminioftheprovirus,respectively.
These, together with internal NcoI and SalI sites at positions 3,728 and
7,596, respectively, were used to assemble the three subgenomic frag-
ments to generate a full-length provirus. Ligation products were used to
transform XL2-MRF bacteria (Stratagene). Resulting transformants were
screened for appropriately sized inserts, transfected into 293T cells,
and tested for infectivity in the TZM-bl assay (73) One functional
clone (pBF1167) was identiﬁed and grown on a large scale (available
from the National Institutes of Health Research and Reference Pro-
gram, Rockville, MD).
BF1167 infectivity and coreceptor usage. BF1167 and TAN2
(SIVcpz) and SG3 (HIV-1) reference clones were transfected into 293T
cells, and supernatants were equilibrated by particle-associated reverse
transcriptase activity as described previously (7, 73). Viral infectivity was
assessed in TZM-bl cells, a HeLa-derived line which has been genetically
modiﬁedtoconstitutivelyexpresshumanCD4,CCR5,andCXCR4andto
containintegratedluciferaseand -galactosidasereportergenesunderthe
control of an HIV-1 LTR (48, 83). For coreceptor analysis, TZM-bl cells
wereseededin96-wellplatesat8,300cells/wellovernightandthentreated
with the CCR5 antagonist TAK-779 (10  M), the CXCR4 antagonist
AMD3100 (1.2  M), or a combination of both for1h( 73). Virus was
addedinthepresenceof40 g/mlDEAE-dextranandremoved48hlater.
Cells werethen lysed andanalyzedforluciferaseactivity(Promega) using
a Tropix luminometer with WinGlow version 1.24 software.
CD4 T cell cultures. Blood was obtained from normal human volun-
teersandhealthy(SIV/HIV-1-uninfected)chimpanzeeshousedattheYe-
rkes Regional Primate Center as described previously (chimpanzee blood
samples were leftover specimens from the annual health check-up) (14).
Brieﬂy, peripheral blood mononuclear cells were isolated using Ficoll
Hypaque Plus (GE Healthcase). CD4
  T cells were enriched using CD4
microbeads and magnetic cell sorting (Militenyi Biotec), stimulated with
staphylococcal enterotoxin B (Sigma-Aldridge) for 12 to 15 h (3  g/ml),
and subsequently cocultivated with autologous monocyte-derived mac-
rophages for optimal activation (14). After 5 to 6 days, CD4
  T cells were
removed from the macrophages, placed into Dulbecco’s modiﬁed Eagle
medium (DMEM) with 10% fetal calf serum (FCS), and incubated with
30 U/ml interleukin-2 (IL-2). After 24 h, 5   10
5 CD4
  T cells were
incubated with transfection-derived viral stocks at a multiplicity of infec-
tion (MOI) of 0.1 (as determined on TZM-bl cells) in 300  l DMEM
containing10%FCSand30U/mlIL-2for16h.CD4
 Tcellswerewashed
three times and plated in 24-well plates in DMEM with 10% FCS and 30
U/ml IL-2, and reverse transcriptase activity was measured in culture su-
pernatants every 3 days to monitor viral replication.
Phylogeneticanalyses.Partialpol(232-bpand892-bp),vpu/env(481-
to 514-bp), gp41 (325- to 465-bp), and gp41/nef (699- to 1,259-bp) se-
quences from the newly characterized viruses were aligned with HIV-1,
SIVcpz, and SIVgor reference sequences (GenBank accession numbers
K03455 for HIV-1 group M HXB2; AJ006022 for HIV-1 group N YBF30;
L20587 for HIV-1 group O ANT70; HQ179987 for HIV-1 group P
U14788; DQ373065 for SIVcpzPtt EK505, DQ373063 for SIVcpzPtt
MB66, DQ373064 for SIVcpzPtt LB7, DQ373066 for SIVcpzPtt MT145,
AF103818forSIVcpzPttUS,AY169968forSIVcpzPttCAM13,X52154for
SIVcpzPtt GAB1, AF115393 for SIVcpzPtt CAM3, AJ271369 for SIVcpz-
Ptt CAM5, FJ424866 for SIVgor CP2139, AF447763 for SIVcpzPts TAN1,
DQ374657 for SIVcpzPts TAN2, DQ373065 for SIVcpzPts TAN3,
JN091691 for SIVcpzPts TAN5, JQ768416 for SIVcpzPts TAN13,
JN091690 for SIVcpzPts UG38, and U42720 for SIVcpzPts ANT) using
Clustal W (34). Regions of the sequences that could not be unambigu-
ously aligned were removed from further analyses. For SIVcpzBF1167,
deduced Gag, Pol, Vif, and Env sequences were aligned with the corre-
sponding protein sequences of the same HIV-1, SIVcpz, and SIVgor ref-
erence strains. Gag/Pol and Pol/Vif protein overlaps were removed from
theNandCterminiofthededucedPolproteinsequences.Inaddition,the
concatenated Pol and Vif alignment was divided into two regions around
a previously reported recombination breakpoint (20, 67). Appropriate
evolutionary models for phylogenetic analyses were selected using Mod-
elTest version 3.7 (51) and ProtTest version 2.4 (1). For nucleotide se-
quence analyses, these were K80 G for the diagnostic 232-bp pol frag-
ment and GTR I G for the longer pol, vpu/env, gp41, and gp41/nef
fragments. For amino acid sequence analyses, the chosen models were
LG I G (Gag), RtREV I G F (Pol), LG I G F (Pol/Vif), and
WAG I G F (Env). Phylogenetic trees were constructed using maxi-
mum likelihood (22) and Bayesian (53) methods, with the latter using a
25% burn-in and using as a convergence criterion an average standard
deviation of partition frequencies of  0.01.
Li et al.
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 For species and subspecies analysis, mtDNA control region (D-loop)
sequenceswerealignedandidenticalsequencesweregroupedintohaplo-
types (see Table S2 in the supplemental material). The evolutionary rela-
tionships of the new haplotypes to each other and to reference sequences
from the database were then determined by phylogenetic analysis. A
neighbor-joining tree is shown in Fig. S1 in the supplemental material.
Nucleotide sequence accession numbers. New SIVcpzPts sequences
have been deposited in GenBank under accession numbers JQ866001,
JQ866003 to JQ866011, JQ866013 to JQ866017, JQ866024, JQ866026 to
JQ866041, JQ866043 to JQ866045, JQ866047 to JQ866052, JQ866055,
JQ866057 to JQ866059, JQ866061 to JQ866066, JQ866068 to JQ866070,
and JX178444 to JX178449. The new P. t. schweinfurthii and Pan paniscus
mitochondrial D-loop sequences are listed in Table S2 in the supplemen-
talmaterial(depositedinGenBankunderaccessionnumbersJQ866072to
JQ866157 and JQ866159 to JQ866296).
RESULTS
SIVcpz infection is endemic and widespread among eastern
chimpanzees. To determine the geographic distribution and
prevalence of SIVcpz in the Democratic Republic of the Congo
(DRC), we conducted a comprehensive, noninvasive (fecal-
based) survey at 41 different collection sites (Fig. 1B). Between
January 2001 and May 2011, we obtained a total of 2,480 fecal
samples north of the Congo River in an area spanning almost
250,000 km
2. Given the vastness of this study area, most samples
were collected by local trackers in the vicinity of their villages.
Whilethisledtosomevariationinsamplequality,wewereableto
obtain samples as far south as Kasese (KE), as far east as Gombari
(GO) and Walikale (WK), as far north as Bondo (BD) and Nian-
gara(NI),andasfarwestasKotakoli(KO)andBumba(BU)(Fig.
1B).Exceptforfoursamplesfrompetchimpanzees,allotherspec-
imens were obtained from wild-living apes within their natural
habitat (Table 1). We also obtained samples from habituated P. t.
schweinfurthii apes in the Budongo Forest (BG) (52) and the Ky-
ambura Gorge (KY) in Uganda and from a nonhabituated group
intheGishwatiForest(GI)inRwanda(49).Therationaleforthese
surveys was to examine whether previous studies had missed iso-
lated foci of SIVcpz infection in east Africa. Since the latter ﬁeld
siteswerewellestablished,samplecollectionandstorageoccurred
under more-controlled conditions.
BeforetestingforSIVcpzantibodiesandnucleicacids,allspec-
imensweresubjectedtomitochondrial(mt)DNAanalysistocon-
ﬁrm their species origin and assess their integrity. This analysis
identiﬁed 495 samples that either were not of chimpanzee origin,
represented fecal mixtures from more than one individual, or
were too degraded for further analysis (Table 1). The remaining
2,070 samples yielded mtDNA (D-loop) sequences which com-
prised 252 different haplotypes (see Fig. S1 in the supplemental
material). All of these were subjected to enhanced chemilumines-
cence (ECL) Western blot analysis,amethodthatdetectsSIVcpz-
speciﬁcantibodiesinfecalextractswithhighsensitivity(0.92)and
speciﬁcity(1.00)evenafterprolongedstorageatambienttemper-
atures (30). Consistent with previous ﬁndings, none of the sam-
ples collected in Uganda and Rwanda were SIVcpz antibody pos-
itive (Table 1). Interestingly, however, 323 fecal specimens from
19 different sites in the DRC exhibited clear evidence of SIVcpz
infection(Fig.2andTable1).Allofthesereactedstronglywiththe
HIV-1p24coreantigen,and11%,62%,and35%alsoreactedwith
p17Gag,reversetranscriptase(p66/p55),andintegrase(p31)pro-
teins, respectively. Surprisingly, half of the samples (54%) also
exhibited cross-reactivity with the HIV-1 envelope antigens
(gp41,gp120,andgp160)whichinsomecaseswasasstrongasthat
of the human positive control (Fig. 2).
To determine the number of SIVcpz-infected apes at the 19
FIG2 DetectionofSIVcpzantibodiesinchimpanzeefecalsamples.Fecalsamplesfromeasternchimpanzees(middle)andbonobos(right)andhumancontrols
(left) were tested by an enhanced chemiluminescence Western blot using HIV-1 antigen-containing strips. Samples are numbered, with letters indicating their
collection site as shown in Fig. 1B. Molecular weights of HIV-1 proteins are indicated. The banding patterns of plasma from HIV-1-infected (positive) and
uninfected (negative) humans are shown for the control.
Widespread SIVcpz Infection in Eastern Chimpanzees
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 sampling locations, we subjected all antibody-positive samples to
microsatellite analyses (see Table S3 in the supplemental mate-
rial). Many of these failed to yield a complete genotype due to
partial sample degradation. To guard against allelic drop out, we
thusallowedmismatchesatuptofourmicrosatellitelociforsam-
ples that shared the same mtDNA haplotype. This conservative
approach identiﬁed a total of 76 SIVcpz-infected apes as a mini-
mum estimate (Table 1). Microsatellite analysis also provided a
quantitativemeasureofredundantsamplingwhich,togetherwith
theproportionofdegradedspecimens,allowedustocalculatethe
prevalenceofSIVcpzinfectionateachcollectionsite.Asshownin
Table 1, analysis of an estimated 567 eastern chimpanzees yielded
an overall prevalence rate of 13.4% (95% conﬁdence interval,
10.7% to 16.5%). As previously observed in Cameroon and
Tanzania, infection rates at individual ﬁeld sites varied widely
(Table1),withhighprevalenceratesobservedinsomecommu-
nities and low levels or absence of infection observed in others. In
general,evidenceforinfectionwasobservedthroughoutthestudy
area, indicating that SIVcpz was not restricted to any one geo-
graphic region. The only exceptions were ﬁeld sites in the north-
ern part of the range, near the Uele River, including Buta (BT),
Bondo (BD), Ango (AN), Niangara (NI), Dingila (DL), Mawa
Gare(MA),Poko(PO),Rungu(RU),andIsiro(IS),whichseemed
to be free of SIV cpz infection. However, the number of usable
samples from these sites was very small (n   77), representing
onlyaminorfraction(3.7%)ofthetotalsurvey.Giventhisandthe
extentofsampledegradation,itisthuspossiblethatinfectedcom-
munities in this northern area were missed. Seven sites exhibited
prevalence rates of 30% or higher, including sites in the far west-
ern (UB) and eastern (MU) parts of the DRC. These results indi-
cate that SIVcpz is common and widespread among most P. t.
schweinfurthiicommunitiesintheDRC(Fig.1B),withprevalence
rates similar to, or exceeding, those previously observed in P. t.
troglodytes apes in Gabon and Cameroon (30, 35a, 41, 78).
No evidence of SIVcpz infection in wild-living bonobos. In
addition to eastern chimpanzees, the DRC is also home to bono-
bos(Panpaniscus),whosehabitatisrestrictedtoforestareassouth
of the Congo River (19). Although a limited number of bonobos
havepreviouslybeentestedincaptivity(77),wild-livingmembers
of this species have never been screened for SIVcpz infection. To
examinewhetherbonobosharborSIV,wecollected543fecalsam-
ples from six ﬁeld sites located throughout the species range (Fig.
1B). All of these were subjected to mtDNA analysis, which identi-
ﬁed 48 degraded or misidentiﬁed samples. The remaining 495
samplesyieldedmtDNA(D-loop)sequencesthatgroupedinto24
distinct haplotypes (see Fig. S1 in the supplemental material).
These were tested by immunoblot analysis, which failed to detect
SIV/HIV cross-reactive antibodies. Western blots were com-
pletely negative for all samples, lacking even faint reactivity with
theGagp24antigen,whichisusuallythemostcross-reactivepro-
tein(Fig.2).Toestimatethenumberofsampledindividuals,spec-
imens from the Ikela (IK), Kokolopori (KR) and Lui-Kotale (LK)
ﬁeld sites were genotyped at eight microsatellite loci (see Table S4
inthesupplementalmaterial).Thisanalysisidentiﬁedaminimum
of 72 individuals and an oversampling factor of 2.03. From this
and the proportion of degraded samples, we estimated that we
screened approximately 244 individuals, none of whom was
SIVcpz infected.
SIVcpzPtsstrainsformamonophyleticclade.Toexaminethe
genetic relationships of the P. t. schweinfurthii viruses from the
DRCtoeachotherandtopreviouslycharacterizedSIVcpzstrains,
all antibody-positive samples were subjected to fecal RNA extrac-
tion and reverse transcription-PCR (RT-PCR) ampliﬁcation. Us-
ing a diagnostic (minipol) primer set (see Table S1 in the supple-
mental material), we ampliﬁed viral sequences from 75 antibody-
positivespecimens.Subsequentscreeningwithgp41andgp41/nef
primers identiﬁed SIVcpz virion RNA in 17 additional samples,
molecularly conﬁrming infection in 25 of the 76 infected individ-
uals(seeTableS3inthesupplementalmaterial).Soastonotmiss
infectionbyotherSIVs,wetestedtheremainingantibody-positive
samples using pan-SIV-speciﬁc primers (see Table S1 in the sup-
plemental material). No other sequences were ampliﬁed, indicat-
ing that the relatively low RT-PCR positivity rate (29%) was the
result of partial sample degradation and not infection by other
primate lentiviruses. All amplicons were sequenced and phyloge-
neticallyanalyzed.Althoughtheminipolsequenceswererelatively
short(232bp),theywereofsufﬁcientlengthtoshowthatallofthe
new DRC viruses were members of the SIVcpzPts lineage. As
shown in Fig. 3, minipol sequences from 20 different individuals
grouped with previously characterized P. t. schweinfurthii viruses
in a clade supported by signiﬁcant bootstrap values.
Toexaminefurtherthephylogeneticrelationshipsofthenewly
derived SIVcpzPts strains, we targeted regions in pol (892 bp),
vpuenv (419 bp), gp41 (405 bp), and gp41/nef (665 bp) for addi-
tional ampliﬁcations. Although longer sequences could be ampli-
ﬁed only from 18 individuals, their phylogeny conﬁrmed the
minipol results (Fig. 4). All newly derived sequences clustered ac-
cording to their subspecies origin, forming a single well-sup-
portedvirallineage.Inaddition,thenewSIVcpzPtsstrainsexhib-
ited evolutionary relationships similar to those previously
described for SIVcpzPtt strains (30, 41, 78): viruses from distant
collectionsitesgenerallyformedwell-separatedcladesorlineages,
whilevirusesfromthesamegeographiclocalewereusuallyclosely
related. For example, viruses from Lubutu (LU) and Mungbere
(MU) each formed discrete clusters, indicating local transmis-
sions. Signiﬁcant clustering was also observed for viruses from
Bongbola (BL) and Mongandjo (MO), suggesting unimpeded vi-
rusﬂowbetweentheseneighboringsites.Interestingly,theBLand
MO strains were also closely related to SIVcpzANT, suggesting a
possible geographic origin for this reference strain. Nonetheless,
phylogeographicclusteringwasnotuniform.Apecommunitiesat
Kabuka (KA) and Parisi (PA) harbored multiple divergent
SIVcpzPts strains, perhaps indicating a greater connectivity of
these communities. There was also evidence of recombination, as
expected in populations coinfected with divergent viral lineages.
One strain from Parisi (PA1) had a mosaic genome, as evidenced
by its discordant clustering in the pol and gp41/nef regions (Fig.
4A and D). Importantly, however, there was no evidence of re-
combinationbetweenanyofthenewlyidentiﬁedDRCvirusesand
SIVcpzPtt strains. In fact, none of the DRC viruses, including
thoseidentiﬁedatthewesternmostcollectionsites(UB,BL,MO),
wereparticularlycloselyrelatedtoP.t.troglodytesviruses.Overall,
SIVcpzPts strains were quite diverse, with nucleotide sequence
distances of up to 25% and 35% in pol and gp41/nef regions, re-
spectively, compared to 22% and 33%, respectively, for members
of the SIVcpzPtt group.
To obtain at least one full-length SIVcpzPts sequence from the
DRC, we selected a sample (BF1167) with a sufﬁciently high viral
loadforwhole-genomeampliﬁcation.Usingstrain-speciﬁcprim-
ers, we ampliﬁed 12 partially overlapping fragments, which to-
Li et al.
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 gether comprised a complete proviral genome (Fig. 5A). Inspec-
tion of the BF1167 consensus sequence revealed uninterrupted
open reading frames for all structural and regulatory proteins as
well as intact regulatory elements. BF1167 also contained all pre-
viously identiﬁed SIVcpzPts signatures (55, 58, 73), including
three amino acid insertions in Gag p24, a conserved PPLP Vif
motif, a short Vpr protein of 95 amino acids, a 5-amino-acid de-
letionattheCterminusofNef,andaninsertionintheectodomain
of gp41. Phylogenetic analysis of full-length Gag, Pol, and Env
proteins showed that BF1167 fell within the SIVcpzPts radiation
(Fig. 6), conﬁrming the relationships derived from the partial ge-
nome sequences.
Generationofareplication-competentSIVcpzPtsclone.The
genomic organization of BF1167 suggested that it may encode a
replication-competent provirus. To test this, we synthesized its
consensus sequence as three subgenomic fragments and ligated
themintoalow-copy-numbervector(Fig.5A).Theresultingplas-
midclonewastransfectedinto293Tcells,andculturesupernatant
was used to infect CD4
  T cell cultures. As shown in Fig. 5B,
BF1167-derived virus replicated efﬁciently and to high titers in
CD4
  T cells from both human (n   4) and chimpanzee (n   4)
donors, with kinetics similar to those of previously characterized
SIVcpzPts (TAN2) and HIV-1 (SG3) strains. Testing its corecep-
tor usage, we found that the infectivity of BF1167 was completely
blocked by the CCR5 antagonist TAK-779 but not by the CXCR4
antagonist AMD3100 (Fig. 5C). This was also true for R5-tropic
reference strains of HIV-1 (YU-2), SIVcpzPts (TAN2), and
SIVcpzPtt (MB897) but not for X4 (NL4-3) and R5/X4 dual-
tropic (WEAU) controls (Fig. 5C). Taken together, these data in-
dicate that the newly derived BF1167 clone encodes an R5-tropic
SIVcpzPts strain capable of infecting both primary human and
chimpanzee CD4
  T cells.
SIVcpzPts strains require more mutational steps than
SIVcpzPtt strains to gain human-speciﬁc Gag matrix and Vpu
adaptations. To evaluate the zoonotic potential of the newly de-
rived DRC viruses, we compared their sequences in protein do-
mains known to be under strong host-speciﬁc selection pressure.
One such site was previously mapped to position 30 (Gag-30) of
the viral matrix protein (82). Inspection of the proteome of all
availableSIVcpzandSIVgorstrainsidentiﬁedaMetorLeuatthis
position. However, when these viruses infected humans, this res-
idue was changed to an Arg in the inferred ancestors of HIV-1
groups M, N, and O and subsequently to a Lys in some M, N, and
O strains (82). To determine the nature of Gag-30 in the DRC
viruses, we ampliﬁed and sequenced the corresponding gag frag-
ment from seven strains (see Table S3 in the supplemental mate-
rial). Interestingly, we found that two of the new viruses (MO1
andUB6)encodedaMetatGag-30,similartoSIVcpzANTandall
FIG 3 SIVcpz strains from the DRC cluster according to their subspecies of
origin. A maximum likelihood tree was constructed from partial (232-bp) pol
sequences (spanning HXB2 coordinates 4682 to 4913). Newly characterized
SIVcpz strains from the DRC are highlighted, with sequences from the same
individual color coded (for individual designations and sample numbers, see
Table S3 in the supplemental material). Previously characterized SIVcpz,
SIVgor, and HIV-1 strains forming the SIVcpzPtt (top cluster) and SIVcpzPts
(bottom cluster) lineages are shown in black. The latter includes reference
strains from Gombe (TAN1, TAN2, TAN3, TAN5, and TAN13) and Ugalla
(UG38) as well as ANT, which is of unknown origin. Asterisks indicate boot-
strap support of  70%. The scale bar represents 0.05 substitutions per site.
Widespread SIVcpz Infection in Eastern Chimpanzees
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 known SIVcpzPtt and SIVgor strains (Fig. 7). However, the other
ﬁve DRC strains encoded a Leu at Gag-30, similar to SIVcpzPts
strains from Gombe (TAN) and Ugalla (UG). We then counted
how many nucleotide substitutions would be required to change
these Gag-30 codons to the HIV-1-speciﬁc residues. Arg is en-
coded by either CGN (where N is A, C, T, or G) or AGR (where R
is A or G), and Lys is encoded by AAR. Thus, changing a Met
(ATG)toArgorLysrequiresonlyasinglenucleotidesubstitution.
Incontrast,LeuisencodedbyCTNorTTR,andchangingaLeuto
Arg or Lys can therefore require one to three nucleotide substitu-
tions (Fig. 7). Examining the Gag-30 codon in all known SIVcpz-
Pts strains, we found that 10 of 14 viruses, including four of seven
DRC strains, encoded Leu using TTA or TTG codons and thus
required at least two mutational steps to acquire the basic Arg or
Lys residue at Gag-30 (Fig. 7).
Human-speciﬁcadaptationhasalsoshapedthefunctionofthe
FIG 4 Phylogeny of SIVcpz from the DRC. Maximum likelihood trees were constructed of partial pol (HXB2 coordinates 3887 to 4778) (A), vpu/env
(HXB2coordinates6062to6578)(B),gp41(HXB2coordinates7836to8264)(C),andgp41/nef(HXB2coordinates8277to9047)(D)sequences.Regions
of ambiguous alignment were removed from this analysis. New SIVcpzPts strains from the DRC are shown in blue, followed by the sample code in
parentheses. Previously characterized SIVcpz, SIVgor, and HIV-1 strains forming the SIVcpzPtt(top cluster) and SIVcpzPts(bottom cluster) lineages are
shown in black. Nodes with both bootstrap support of  70% and a Bayesian posterior probability of  0.95 are indicated by asterisks. The scale bar
represents 0.05 substitutions/site.
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 HIV-1 Vpu protein (18, 36, 61). Vpu modulates the cell surface
expressionofanumberofimmunoregulatoryproteins,including
the CD4 receptor, the natural killer (NK) cell ligand NTB-A, and
the lipid antigen-presenting protein CD1d (13, 40, 63). In HIV-1,
Vpu also counteracts tetherin, an innate restriction factor that
inhibitsthereleaseofnascentvirusparticlesfrominfectedcellsby
“tethering” them to the cell surface (42, 46, 75). In SIVcpz and
SIVgor,Vpulacksthisfunctionandthesevirusesantagonizeteth-
erinviatheirNefproteins(61).However,thesesameNefproteins
are inactive against human tetherin due to a ﬁve-amino-acid de-
letionthatconfersresistance(61).Togaugehowdifﬁcultoreasyit
would be for the newly characterized DRC strains to acquire an-
tihuman tetherin activity, we aligned their Vpu sequences, as well
as those of available SIVcpzPtt and SIVgor strains, to the HIV-1
group M Vpu consensus sequence (Fig. 8). Focusing in particular
on the N-terminal transmembrane domain (TMD), which has
been shown to interact directly with tetherin via four amino acid
residuesonthesamefaceofitsmembrane-spanninghelix(68),we
counted the number of nucleotide substitutions that would be
required to gain a functional A/GxxxAxxxAxxxW motif (15, 31,
68, 80, 81). The results ranged from a single substitution for a
subset of SIVcpzPtt strains to nine changes for the SIVcpzPts
strainANT,withtheclosestchimpanzeerelativesofHIV-1groups
M (MB879 and LB715) and N (EK505) requiring only one and
twosubstitutions,respectively(Fig.8).Althoughtheadaptivedis-
tance depended on the particular virus, SIVcpzPtt and SIVgor
strains typically required fewer changes (median, 4; range, 1 to 8)
thanSIVcpzPtsstrains(median,7;range,3to9)togainthehelix-
helix interaction motif, suggesting that they might be more prone
tohumanadaptation.Wealsoexaminedthecytoplasmicdomains
of the various Vpu proteins for the presence or absence of func-
tional motifs, including a Yxx  motif (56), a DSGxxS  -TrCP
binding site (39), and a putative ExxxLV trafﬁcking signal (33),
thathavepreviouslybeenshowntoplayaroleintetherintrafﬁck-
ing and/or degradation. Again, all of these domains were more
commonly found in the Vpu proteins of SIVcpzPtt and SIVgor
strainsthanintheVpuproteinsofSIVcpzPtsstrains(Fig.8),with
only one of 16 P. t. schweinfurthii viruses containing the ExxxLV
motif that was recently shown to be required for efﬁcient cell-free
virion release from CD4 T cells (33). Thus, as a group, SIVcpzPts
strainsseemtorequireamuchgreaternumberofmutationalsteps
togainhuman-speciﬁcadaptationsthandoSIVcpzPttandSIVgor
strains.
DISCUSSION
AlthoughlongknowntoharborSIVcpzinthewild(59,60),wild-
living eastern chimpanzees have not been thought to represent a
virus reservoir. This is because previous ﬁeld studies in Uganda,
Rwanda, and Tanzania failed to uncover infected apes at most
locations, except for communities in Gombe National Park and
FIG 5 Generation and biological characterization of a replication-competent
SIVcpzPtsmolecularclone.(A)IndividualRT-PCRamplicons(orangeboxes)
of BF1167 are shown in relation to the SIVcpz genome. Fragments are drawn
to scale, with nucleotide sequences numbered starting at the beginning of the
R region in the 5= LTR (see scale bar). Three subgenomic fragments bound by
MluI, NcoI, SalI, and ApaI restriction sites were synthesized and then assem-
bled to produce a full-length provirus (blue line). (B) The replication kinetics
of BF1167-derived virus in human (top) and chimpanzee (bottom) CD4
  T
cells are shown in relation to those of HIV-1 (SG3; blue) and SIVcpzPts
(TAN2; green) reference strains (x axis, days postinfection; y axis, nanograms
of reverse transcriptase [RT] activity per ml of culture supernatant). Average
values (and one standard deviation) from different experiments (indicated in
parentheses) are shown. (C) TZM-bl cells were pretreated with AMD3100
(inhibitorofCXCR4),TAK779(inhibitorofCCR5),orbothpriortoaddition
of the virus preparations indicated. Virus infectivity is plotted on the vertical
axis as a percentage of the untreated control. Virus derived from the reference
clones NL4.3 (X4 tropic), YU2 (R5 tropic), and WEAU1.6 (dual tropic) and
SIVcpzPtt (MB897) and SIVcpzPts (TAN2) strains were included as controls.
BF1167 is an R5-tropic virus.
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 the Masito-Ugalla region of western Tanzania (29, 54, 55, 59, 60,
66). However, since these areas of east Africa comprise only a
small part of the P. t. schweinfurthii range (Fig. 1), we reasoned
thattheobservedpaucityofinfectionsmightnotberepresentative
of the entire subspecies. To test this hypothesis, we targeted
wild-living ape populations in the DRC, a country believed to
be home to as many as 200,000 P. t. schweinfurthii apes and
50,000 bonobos (10, 19). To cover this vast area, we recruited
local teams of trackers to collect ape fecal samples in the vicin-
ity of their villages. Although this resulted at times in pro-
longed sample storage at ambient temperatures and, thus, par-
tial specimen degradation, we were able to procure an
unprecedented number of specimens from a wide variety of
different locales (Table 1). This allowed us to assess the preva-
lence and geographic distribution of SIVcpz throughout the
Congo Basin and to determine whether wild-living bonobos,
which have not previously been tested for SIV infection, are
natural carriers of this virus. We also screened additional com-
FIG 6 Evolutionary relationships of BF1167 full-length genome sequences. Maximum likelihood trees were inferred from amino acid (aa) sequence
alignments of the major proteins, including Gag (420 aa; HXB2 coordinates 790 to 2280) (A), N-terminal Pol (630 aa; HXB2 coordinates 2295 to 4184)
(B),C-terminalPol/Vif(453aa;HXB2coordinates4185to5556)(C),andEnv(729aa;HXB2coordinates6324to8792)(D);thePolproteinwasseparated
into two fragments at a point where a recombination breakpoint was previously identiﬁed in HIV-1 group N. The BF1167 sequence is shown in blue.
Previously characterized SIVcpz, SIVgor, and HIV-1 strains forming the SIVcpzPtt (top cluster) and SIVcpzPts (bottom cluster) lineages are shown in
black. Nodes with both bootstrap support of  70% and a Bayesian posterior probability of  0.95 are indicated by asterisks. The scale bar represents 0.05
amino acid replacements/site.
Li et al.
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 munitiesinUgandaandRwandatodeterminewhetherisolated
foci of SIVcpz infection had previously been missed.
Testing2,070fecalsamplesfromanestimated567P.t.schwein-
furthii apes, we identiﬁed 323 specimens from 76 individuals that
harbored SIVcpz-speciﬁc antibodies, yielding an overall preva-
lence of 13.4% (95% conﬁdence interval, 10.7% to 16.5%). Since
chimpanzees in the northern DRC differ from their east African
counterpartsinanumberofkeybehavioraltraits(suchasground
nestingandlackoftermiteﬁshing),whichsuggestsalongstanding
cultural separation (25), we also analyzed the DRC populations
separately. Excluding samples from Rwanda and Uganda, we
found that the remaining sites exhibited a prevalence of 14.9%.
Remarkably, this estimate is 2.5 times higher than the prevalence
previouslydeterminedforP.t.troglodytesapesinCameroon(41).
Inthelatterstudy,analysisof1,217fecalsamplesfrom25different
ﬁeld sites south of the Sanaga River yielded an overall prevalence
of 5.9% (95% conﬁdence interval, 4.3% to 7.9%). Although in-
fectedapeswereidentiﬁedat10ofthe25ﬁeldsites,localinfection
levels were relatively low (41). Only one Cameroonian site exhib-
ited a prevalence of greater than 30% (41), compared to seven
such sites in the DRC (Table 1). Since the methods of fecal collec-
tionanddiagnosingSIVcpzwereverysimilar,theobserveddiffer-
ences cannot be explained by ascertainment biases or technical
differences. Moreover, infection rates in the DRC represent min-
imumestimates,giventhatmanysampleswerepartiallydegraded.
Although SIVcpz is generally unevenly distributed among wild-
living chimpanzees (29, 35a, 55, 59), our data indicate that P. t.
schweinfurthiiapesareatleastaswidelyandcommonlyinfectedas
P. t. troglodytes apes. A recent study of wild-living P. t. troglodytes
apesinGabonconﬁrmedthis,identifyingSIVcpzinfectionatonly
threeof10locations,withhigh-levelinfectiondetectedatonlyone
of these sites (35a). In contrast, the newly screened communities
intheBudongoReserve(BG),theKyamburaGorge(KY),andthe
Gishwati Forest (GI) were all virus negative, further supporting
the notion that SIVcpz is absent from the extreme eastern edge of
the P. t. schweinfurthii range except for isolated communities in
western Tanzania. It remains unknown whether SIVcpz was once
present there and has subsequently gone extinct or whether its
eastward spread was obstructed by habitat loss and/or other bar-
riers such that certain communities were never exposed.
In contrast to eastern chimpanzees, none of the 495 bonobo
samples from an estimated 244 individuals were SIV antibody
positive(Table1).Althoughbonobosweresampledatfewerloca-
tions than P. t. schweinfurthii apes, the six ﬁeld sites were widely
distributedthroughoutthebonoborange(Fig.1B).Moreover,for
all but one ﬁeld site (BJ), signiﬁcant numbers of samples were
tested (Table 1), arguing against the possibility that low-level in-
fections were missed. There were also no differences in the ways
bonobo and eastern chimpanzee samples were collected, stored,
and transported. Thus, sample degradation cannot be invoked as
an explanation for the negative Western blot results. Based on
these data, it seems likely that bonobos are free of SIVcpz infec-
tion. This is consistent with a previous study that failed to detect
SIVcpz antibodies in the blood of 26 captive bonobos (77). It is
also consistent with the fact that bonobos and eastern chimpan-
zees have nonoverlapping ranges (Fig. 1). However, given that
westerngorillasareonlyrarelyinfectedwithSIVgor(41),itwillbe
important to exclude isolated infections of bonobos by testing
additional individuals from a wider range of locations. It should
also be noted that bonobos, like chimpanzees, are exposed to a
varietyofSIVsbecausetheyhuntandeatsmallerprimates,includ-
ing different species of guenons (70, 71), which carry their own
types of SIV (2). These monkey SIVs are genetically quite diver-
gent from HIV-1/SIVcpz and may elicit antibodies that do not
cross-react with HIV-1 proteins (2, 43). It will thus be important
toincludeadditionalSIVantigensinfuturenoninvasivescreening
approaches to examine whether bonobos harbor such viruses.
Previous evolutionary studies have shown that SIVcpz se-
quences form two highly divergent lineages, SIVcpzPtt and
SIVcpzPts, according to their subspecies of origin (64–66). These
studies also revealed that all groups of HIV-1 and SIVgor cluster
withintheSIVcpzPttlineage,thusidentifyingP.t.troglodytesapes
as the original source of both human and gorilla viruses (24, 47,
72,79).However,exceptforANT(76)andtheonlypartiallychar-
acterized DRC1 virus (84), all other SIVcpzPts strains were de-
rived from infected apes in Gombe and Ugalla (29, 54, 55), thus
leaving the evolutionary history of viruses from the remaining
partsoftheP.t.schweinfurthiirangeopentoquestion(45).Inthis
study,wetestedallantibody-positivefecalsamplesfromtheDRC
for the presence of SIVcpz sequences. Using gag, pol, vpu, and env
primers, we were able to amplify virion RNA from 25 of the 76
infected individuals (see Table S3 in the supplemental material).
FIG 7 Adaptive requirements of SIVcpz at Gag-30. The codon at position 30
of the Gag matrix protein is shown for 14 SIVcpzPts strains, including seven
newvirusesfromtheDRC.Tenofthese14virusesencodedaLeuusingTTAor
TTG codons at Gag-30, codons which require at least two nucleotide changes
tobecomeArg(CGNorAGR)orLys(AAR)codons.Incontrast,allsequenced
SIVcpzPtt (n   15) and SIVgor (n   3) strains contain a Met ATG codon,
which requires only a single substitution to change to either human-speciﬁc
signature.
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 Although this recovery rate was lower than in previous ﬁeld stud-
ies, we obtained SIVcpz sequences from 14 of the 19 positive lo-
cations(Fig.1B).Importantly,wefoundthatallofthenewviruses
clustered with previously characterized SIVcpzPts strains in all
genomic regions analyzed (Fig. 3, 4, and 6). While some grouped
according to their ﬁeld site of origin, phylogeographic clustering
seemed less pronounced in the DRC than previously observed in
Cameroon (30, 78). This may be because the largely contiguous
forests in the DRC have provided for greater connectivity and,
thus, exchange of divergent viruses over longer distances. None-
theless, all DRC viruses fell within the SIVcpzPts radiation, form-
ingasinglewell-supportedphylogeneticlineagethatalsoincluded
viruses from Gombe and Ugalla (Fig. 3, 4, and 6). This strict sub-
species-speciﬁc clustering indicates that P. t. schweinfurthii apes
have been effectively isolated from P. t. troglodytes apes for a con-
siderable period of time. It also conﬁrms that chimpanzees in the
DRC were not the source of any known strain of HIV-1 (84).
GiventhatSIVcpzinfectionratesinwild-livingchimpanzeesin
the DRC are at least as high, if not higher, than in Cameroon and
Gabon, it seems striking that SIVcpzPts strains have never been
found in humans. There are at least three potential explanations
which are not mutually exclusive. One possibility is that humans
in the DRC are less frequently exposed to SIVcpz. Although it
remains unknown exactly how humans acquired the ape precur-
sors of HIV-1 groups M, N, O, and P, cross-species transmission
must have occurred through cutaneous or mucous membrane
exposure to infected ape blood and/or body ﬂuids which occurs
most frequently in the context of bushmeat hunting (24). While
ﬁrm data concerning the frequencies and types of human-ape
interactions in the DRC are lacking, it is believed that hunting
varies regionally due to differences in local traditions and prefer-
ences,withsometribeshavingtaboosagainsttheconsumptionof
apes (45). Thus, human exposure to SIVcpz may have historically
been lower in the DRC than in west central Africa, and this may
FIG 8 Adaptive requirements of SIVcpz in transmembrane and cytoplasmic domains of Vpu. Vpu amino acid sequences of SIVcpzPtt, SIVgor, and
SIVcpzPts strains are aligned in their transmembrane domain to the corresponding region of the HIV-1 group M consensus as previously described (36).
Dashes indicate gaps introduced to optimize the alignment. Gray boxes highlight residues of a conserved helix-helix interaction motif (G/AxxxAxxxA
xxxW, where “x” may be any amino acid) that is required to counteract human tetherin (68, 80). The minimum number of mutational steps needed to change
the corresponding amino acid to that of the human residue is indicated on the right. Columns on the far right indicate the presence ( ) or absence (blank) of
previously described transport and/or degradation motifs in the intracellular domain of Vpu. These include a Yxx  motif scored as Yxx(L/M/V/I/F/W) (8, 21,
56), a  -TrCP ubiquitin-dependent degradation signal scored as D(S/D/E)Gxx(S/D/E) (28, 39), and a putative trafﬁcking signal scored as (D/E)xxxL(L/V/I/M)
(33).
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 explainthelackofSIVcpzPtszoonoses.However,evenifthiswere
the case, this barrier is clearly no longer in place. Bushmeat hunt-
ing in the DRC, including the poaching of chimpanzees, has been
on the rise in the past decade due to political turmoil and eco-
nomic changes (5). A recent study of apes north and south of the
Uele River documented a major increase in chimpanzee killing
duetoaninﬂuxofartisanaldiamondandgoldminers(26).Thus,
increased surveillance of humans in these areas for SIVcpzPts and
other ape-derived infections may be warranted (6, 11, 38).
A second explanation is that SIVcpzPts infections of humans
may, in fact, have occurred but gone unrecognized because of
limited human sampling and a lack of speciﬁc tests. The great
majority of HIV-1 infections in the DRC and elsewhere are diag-
nosed serologically, using enzyme-linked immunosorbent assays
(ELISAs) or rapid-test immunoblot approaches. Despite their ge-
netic diversity, many of the ape infections characterized here ex-
hibited a Western blot proﬁle indistinguishable from that of the
positive HIV-1 control (Fig. 2). It is thus possible that a human
infected with such a virus may be misdiagnosed as being infected
by HIV-1 group M, especially since the vast majority of HIV-1
infections in the DRC are not molecularly conﬁrmed. However,
suchSIVcpzPtszoonoses—iftheyhaveindeedoccurred—areun-
likely to have infected large numbers of people, because more-
substantive outbreaks would likely have been detected by existing
surveillance programs, such as those that discovered the very rare
NandPgroupsofHIV-1(47,67).TheapparentlackofSIVcpzPts
zoonosesmayalsoreﬂectregionaldifferencesinhumantransmis-
sion networks, since sporadic introductions into less-dense, less-
urban, and/or less-well-connected populations would be more
likely to result in dead-end infections.
A third possibility is that SIVcpzPts strains face greater adap-
tive hurdles before they can replicate and spread efﬁciently in the
human host. Examining SIVcpz proteomes for amino acids that
were highly conserved in the ape precursors of HIV-1 but that
changed each time these viruses crossed the species barrier to hu-
mans, we previously found a Met or Leu in all SIVcpz/SIVgor
strainsbutanArgintheinferredancestorsofHIV-1groupsM,N,
and O and a Lys in some HIV-1 strains (82). We also showed that
changingMet/LeuatGag-30toArg/Lysgreatlyenhancedtherep-
lication ﬁtness of SIVcpz strains in human tonsil cultures, while
the opposite was true for HIV-1 strains that contained the ape-
speciﬁc Gag-30 residues (7). These studies provided compelling
evidence that host-speciﬁc adaptation at Gag-30 is required for
efﬁcient replication of SIVcpz in human lymphatic tissue. When
we determined the nature of the Gag-30 residue in all available
SIVcpzPts strains, including the new viruses from the DRC, we
found that most require twice as many mutational steps as
SIVcpzPttandSIVgorstrainstoadaptatGag-30(Fig.7).Substan-
tial adaptive hurdles were also identiﬁed for the SIVcpz Vpu pro-
tein (18, 36, 61). It has been shown that upon cross-species trans-
mission, the ape precursors of HIV-1 had to switch from Nef- to
Vpu-mediated tetherin antagonism (36, 61). However, only the
pandemicMgroupvirusesacquiredefﬁcientantitetherinactivity,
while the much-less-prevalent group N, O, and P viruses either
failed to gain this activity or lost other Vpu functions (36, 61, 62,
81, 85, 86). These ﬁndings have been taken to indicate that suc-
cessful SIV zoonoses require effective tetherin antagonism (23).
WhenwecomparedapevirusVpusequencestothatoftheHIV-1
group M consensus, we found that some SIVcpzPtt Vpu proteins
required only very few changes to gain key functional motifs
(Fig.8).Incontrast,mostSIVcpzPtsVpuproteinsrequiredasub-
stantially larger number of substitutions to acquire these same
human-speciﬁc signatures (Fig. 8). Although counting numbers
of mutational steps represents a gross oversimpliﬁcation of the
adaptation process, our analyses suggest that certain SIVcpzPtt
strainsarebetterequippedtobecomenewhumanpathogensthan
most SIVcpzPts strains. The fact that the reconstructed BF1167
genome(aswellasthoseofotherSIVcpzPtsstrains)replicateswell
in human CD4
  T cells (Fig. 5) does not argue against this, since
suchmaximallystimulatedculturesdonotaccuratelyrecapitulate
the conditions of viral replication and transmission in vivo (7).
Insummary,wereportherethatwild-livingP.t.schweinfurthii
populations are much more widely and commonly infected with
SIVcpz than previously appreciated. This is particularly true for
communities in the northern DRC which represent a large con-
tinuous population that seems to provide opportunity for virus
ﬂow across vast areas. Whether these viruses have a reduced po-
tential to infect humans and cause epidemic outbreaks is not
known but should be investigated. In particular, studies of host
restriction mechanisms that may have prevented the spread of
thesevirusesinthehumanpopulationwouldbeinformative.This
is now possible, since well-characterized reagents, including a
large panel of SIVcpzPtt and SIVcpzPts infectious molecular
clones, are available for study. The high prevalence of SIVcpzPts
infection also has implications for conservation efforts. SIVcpz is
quite pathogenic and has been shown to negatively impact chim-
panzee population growth (17, 29, 54, 74). Given that the DRC is
home to half of the world’s remaining chimpanzees, it will be
critical to determine in much greater detail to what extent SIVcpz
has penetrated these populations so that the impact of this infec-
tion on the long-term survival of this species can be determined.
Finer-grainedprevalenceandnaturalhistorydatawillalsobecrit-
ical for attempts to limit the spread of SIVcpz in wild ape popula-
tions, for example, through the use of adeno-associated virus
(AAV)-mediated gene transfer of antibodies that neutralize
SIVcpz as a prophylactic or therapeutic vaccine (4, 27) which can
potentially be administered in wild settings (57).
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